Medicure annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Medicure R&D Spending Growth & History (MCUJF)
Medicure's r&d spending was $3.2M for fiscal 2025.
View full Medicure company overviewMedicure annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.2M | $98,000 | +3.18% |
| 2024 | 2024-12-31 | $3.1M | $675,000 | +28.05% |
| 2023 | 2023-12-31 | $2.4M | −$348,000 | −12.64% |
| 2022 | 2022-12-31 | $2.8M | $958,000 | +53.34% |
| 2021 | 2021-12-31 | $1.8M | −$1.5M | −45.56% |
| 2020 | 2020-12-31 | $3.3M | −$1.1M | −24.14% |
| 2019 | 2019-12-31 | $4.3M | −$2.3M | −34.90% |
| 2018 | 2018-12-31 | $6.7M | $1.5M | +29.78% |
| 2017 | 2017-12-31 | $5.1M | $1.5M | +41.82% |
| 2016 | 2016-12-31 | $3.6M | −$1.2M | −25.39% |
| 2015 | 2015-12-31 | $4.9M | — | — |
Medicure quarterly r&d spending
Q1.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $608,000 | −$133,000 | −17.95% |
| Q1 2026 | 2026-03-31 | $855,000 | $285,000 | +50.00% |
| Q4 2025 | 2025-12-31 | $1.2M | — | — |
| Q3 2025 | 2025-09-30 | $717,000 | — | — |
| Q2 2025 | 2025-06-30 | $741,000 | — | — |
| Q1 2025 | 2025-03-31 | $570,000 | −$106,000 | −15.68% |
| Q1 2024 | 2024-03-31 | $676,000 | — | — |
Medicure r&d spending trends
Over the last five fiscal years, Medicure's r&d spending decreased from $3.3M to $3.2M, a change of −$120,000. The latest reported quarter, Q2 2026, shows $608,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medicure source filings ↗